NASDAQ · AUPHHealthcarePharmaceuticals

Aurinia Pharmaceuticals news

$16.42−0.61%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days1English, de-duplicated

Positive1100% of coverage

Neutral00%

Negative00% of coverage

About Aurinia Pharmaceuticals

No recent articles focused on Aurinia Pharmaceuticals.

Also mentions AUPH

Articles that tag AUPH but are mainly about other companies.

Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight

GlobeNewswire Inc.Sep 14, 1:00 PM ET▲ Positive

LUPKYNIS (voclosporin) is an FDA-approved therapy and the company launched PRESERVE Phase IV study evaluating combination therapies, demonstrating continued market expansion efforts.

7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments

GlobeNewswire Inc.Apr 10, 4:59 AM ET▲ Positive

Listed as an emerging player with pipeline products in the high-growth SLE/LN market

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology